Overview
The Ministry of Commerce & Industry announced that India’s pharmaceutical sector, valued at about $60 billion, aims to double its size within the next five years. Union Minister Piyush Goyal invited global pharma firms to partner with India for innovation‑driven, affordable healthcare.
Key Developments
- India will move beyond generic medicines to high‑value, innovation‑led products while keeping drugs affordable.
- Invitation to global companies to set up R&D, clinical trials, and manufacturing units in India.
- Emphasis on three pillars – trust, innovation and partnerships.
- India’s economy grew 7.7 % (constant prices) in FY 2025‑26 despite geopolitical tensions and US tariffs.
- Preferential market access under existing Free Trade Agreements (FTAs) covering 50+ countries.
Important Facts
- Generic medicines constitute 80‑90 % of volume but only 10‑15 % of value in the US market, highlighting India’s cost advantage.
- India supplies 65‑70 % of World Health Organization (WHO) vaccine requirements.
- India hosts the highest number of US FDA‑approved pharma plants outside the United States.
- Patent filings have risen by nearly 100 % in recent years, reflecting growing R&D activity.
- The Biopharma Shakti programme and a $10 billion innovation fund aim to accelerate new drug development.
- During COVID‑19, India provided medicines free of cost to over 100 countries and kept export prices at pre‑pandemic levels.
UPSC Relevance
For GS Paper II (Polity) the role of the Union Minister illustrates how executive decisions shape trade policy. GS Paper III (Economy) benefits from data on sector growth, FTAs, and the innovation fund, useful for questions on industrial policy and export‑import dynamics. The emphasis on affordable medicines links to GS Paper IV (Ethics) and health‑related governance, especially the principle of “Vasudhaiva Kutumbakam” that underpins India’s equitable health outreach.
Way Forward
India will continue to attract foreign investment by offering zero‑duty access for many pharma products under its FTAs. Strengthening the trust pillar through compliance with global GMP standards and expanding FDA‑approved facilities will reassure partners. The government plans to scale up the Biopharma Shakti programme, encouraging joint R&D and clinical trials. Long‑term collaborations, beyond crisis‑driven aid, are expected to create a resilient, innovation‑centric pharma ecosystem that serves both domestic needs and global health security.